Norris Perne & French LLP Bluebird Bio, Inc. Transaction History
Norris Perne & French LLP
- $1.31 Billion
- Q1 2024
A detailed history of Norris Perne & French LLP transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 10,000 shares of BLUE stock, worth $12,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$12,400
Previous $13,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BLUE
# of Institutions
171Shares Held
104MCall Options Held
814KPut Options Held
1.23M-
Black Rock Inc. New York, NY15.2MShares$18.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.5MShares$13 Million0.0% of portfolio
-
Granahan Investment Management, LLC Waltham, MA7.71MShares$9.56 Million0.35% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN6.39MShares$7.93 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.24MShares$7.74 Million0.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $95.6M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...